Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...

TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

India's Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of hair loss.

Use of lasers for dermatologic conditions in pediatric patients brings challenges, from psychosocial and informed consent ...

Thermo Fisher continues its growth through acquisitions, innovative product launches, and a solid financial foundation. The ...

Certain habits can make alopecia areata worse. Knowing what to avoid when you have alopecia areata may help prevent hair loss.

Alumni Nicole Friedland (Merrill ’89, community studies) and Brett King (Crown ’92, chemistry) both spoke at the National ...

Children of various racial and ethnic minority groups have a higher prevalence of alopecia areata than non-Hispanic White children.

New treatment for alopecia areata brings hope to local teen patients by: Dina Bair, Katharin Czink Posted: Jun 25, 2025 / 07:56 PM CDT Updated: Jun 25, 2025 / 07:56 PM CDT ...

Alopecia areata is a prevalent autoimmune condition marked by non-scarring hair loss, affecting nearly 2% of the population during their lifetime. The condition involves the breakdown of the ...